



National Brain Tumour Registry

CNS SSCRG Work Programme

Visualising Low Grade Gliomas Care Patterns, East of England only


Produced by NBTR 2011 (updated March 2012)

Visualising low grade glioma pathways using a novel informatics tool known as i2, East of England data only.


The Eastern Cancer Registration & Information Centre (ECRIC) have been using i2 for a number of years now to look at patient pathways. The software plots where a patient travels throughout their cancer journey.

The software shows two main nodes, the patient and the hospital. These are then linked by the treatments they received.


Diagnosis only




Diagnosis & Surgery



Diag, Surgery & Chemo



Diag, Surgery, Chemo & Radio



Low Grade Gliomas


The study of the low grade gliomas was split into four main age bands:

- 0-16
- 17-24
- 25-50
- 51 and over

Due to the nature of the i2 visualisation tool all data is anonymised and no time frame listed as the data is sensitive and possibly disclosive. We therefore have produced this report as a summary report to show how the patients move throughout the region and to show how powerful the tool and the data can be.

More detailed reports can be produced on request from individual Trusts with the correct permissions.


0-16 Years i2 chart



0-16 years detailed results

- 91% patients diagnosed at main paediatric neuro-oncology specialist centres
- 9% patients diagnosed at other hospitals
- Of the total:
 - 72% went on to have Surgery
 - 97% at main paediatric neuro-oncology centres
 - 5% went on to have Radiotherapy
 - 18% went on to have Chemotherapy
 - Of whom
 - » 20% vincristine, carboplatin, etoposide
 - » 40% vincristine, carboplatin
 - » 10% SIOP LGG 2004 trial
 - » 30% no details


25-50 Years i2 chart



25 – 50 Years detailed results

- 65% patients diagnosed at specialist neuro-oncology centres
- 35% patients diagnosed at other hospitals
- Of the total:
 - 87% went on to have Surgery
 - 68% at specialist neuro-oncology centres
 - 32% at other non specialist centres
 - 50% went on to have Radiotherapy
 - 48% at specialist neuro-oncology centres
 - 52% at other non specialist centres
 - 6% went on to have Chemotherapy
 - Of whom
 - » 100% Temozolomide

51 + Years i2 chart



51+ Years detailed results

- 54% patients diagnosed at specialist neuro-oncology centres
- 46% patients diagnosed at other hospitals
- Of the total:
 - 52% went on to have Surgery
 - 75% at specialist neuro-oncology centres
 - 25% at other non specialist centres
 - 29% went on to have Radiotherapy
 - 21% at specialist neuro-oncology centres
 - 79% at other non specialist centres
 - 13% went on to have Chemotherapy
 - Of whom
 - » 50% Temozolomide
 - » 17% PCV (procarbazine, lomustine, vincristine)
 - » 34% No details

Summary of results

- Patients diagnosed and treated with cancer follow complex pathways involving multiple organisations.
- Tracking patients across their care pathway and monitoring outcome is essential if we are to deliver the best care.
- i2 has provided us with a first step to build this complex picture.